Ardent Health Partners, LLC Ratios | P/E, ROE & Valuation

On the Key Ratios page for Ardent Health Partners, LLC (ARDT), the latest P/E of 19.8 frames valuation, while ROE 5.21% and ROIC 9.26% indicates profitability and capital efficiency. Together with the current ratio of 2.10 and debt-to-equity 1.68, these signals help you judge whether valuation is supported by fundamentals across the historical rows.

Financial Performance Ratios

ARDT Historical Per Share Metrics

8 years
Metric (FY)TTM2024202320222021201820172016
Revenue per Share$45.21$45.05$37.76$35.81$34.00$29.52$21.30$14.93
Net Income per Share$0.55$1.59$0.35$1.32$1.08$-1.01$-0.25$0.10
Operating Cash Flow per Share$3.60$2.38$1.55$-0.27$1.03$1.13$0.85$0.61
Free Cash Flow per Share$2.12$0.96$0.59$-1.32$0.06$-0.01$-0.01$0.03
Cash per Share$5.11$4.20$3.05$3.18$0.00$0.42$0.51$0.66
Book Value per Share$12.29$11.49$7.55$7.33$0.00$5.05$5.39$2.81
Tangible Book Value per Share$5.47$4.48$1.12$0.90$0.00$-1.33$-0.97$0.57
Interest Debt per Share$16.35$17.73$17.19$17.24$0.00$9.71$7.26$1.90
CAPEX per Share$1.48$1.42$0.96$1.05$0.97$1.14$0.86$0.57

ARDT Historical Valuation Ratios

8 years
Metric (FY)TTM2024202320222021201820172016
Price to Earnings (P/E)19.8410.7545.7512.1814.92-15.83-63.51155.05
Price to Book (P/B)1.1423.433.606.835.998.49
Price to Sales (P/S)0.240.380.430.450.470.540.751.08
Enterprise Value to EBITDA7.737.1712.177.96014.113.6216.88
EV to Sales0.480.670.790.8300.831.051.15
EV to Operating Cash Flow6.0912.6619.21-110.35021.7126.3228.12
EV to Free Cash Flow10.3331.2750.54-22.340-3235.35-1525.02666.2
Enterprise Value$3.11B$3.99B$4.26B$4.23B$0.00$3.47B$3.14B$2.41B

ARDT Historical Profitability Ratios

8 years
Metric (FY)TTM2024202320222021201820172016
Return on Equity (ROE)5.21%18.59%7.50%29.56%0.00%-43.13%-9.44%5.48%
Return on Invested Capital (ROIC)9.26%8.46%5.14%4.12%0.00%6.34%0.10%9.08%
Return on Tangible Assets1.81%5.22%1.32%4.80%0.00%-7.75%-2.41%1.90%
Earnings Yield5.06%9.30%2.19%8.21%6.70%-6.32%-1.57%0.64%
Free Cash Flow Yield19.22%5.64%3.66%-8.23%0.34%-0.05%-0.09%0.16%
Dividend Yield0.00%0.00%0.00%7.60%2.70%0.00%0.00%0.00%

ARDT Historical Liquidity & Financial Strength

8 years
Metric (FY)TTM2024202320222021201820172016
Current Ratio2.11.941.631.7401.381.451.44
Interest Coverage9.746.363.512.433.441.381.723.15
Income Quality3.541.054.11-0.20.95-1.12-3.355.87
Debt to Equity1.682.023.573.7403.82.520.9
Debt to Assets42.92%46.05%50.65%49.14%0.00%45.91%40.12%22.15%
Net Debt to EBITDA3.843.15.63.6304.893.811.03

ARDT Historical Efficiency Ratios

8 years
Metric (FY)TTM2024202320222021201820172016
Receivables Turnover9.28.036.988.3807.876.618.06
Payables Turnover10.446.320.32.980000
Inventory Turnover38.6722.021.348.910000
Days Sales Outstanding39.6545.4652.3243.54046.455.1845.26
Days Payables Outstanding34.9657.781229.8122.590000
Days of Inventory on Hand9.4416.57273.3740.950000

ARDT Historical Market Metrics

8 years
Metric (FY)TTM2024202320222021201820172016
Enterprise Value to EBITDA7.737.1712.177.96014.113.6216.88
Market Cap$1.56B$2.26B$2.30B$2.30B$2.30B$2.26B$2.26B$2.26B
Enterprise Value$3.11B$3.99B$4.26B$4.23B$0.00$3.47B$3.14B$2.41B
Dividend Yield0.00%0.00%0.00%7.60%2.70%0.00%0.00%0.00%
Payout Ratio0.00%0.00%0.00%92.54%40.27%0.00%0.00%0.00%

Frequently Asked Questions

How does Ardent Health Partners, LLC’s P/E ratio compare with its history?

On this page, ARDT's current P/E is 19.8, compared with a multi-year average around 43.1. A lower P/E versus its own history is a calculated gap versus that average—not a conclusion that the stock is cheap. Pair it with profitability and earnings quality in the table (for example ROE/ROIC) to see whether the multiple moved with earnings.

What is Ardent Health Partners, LLC market cap?

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $1.56B. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

How does Ardent Health Partners, LLC’s P/E compare with its industry?

There is no P/E Tickerplace rates as good. Compare the P/E on this page with Ardent Health Partners, LLC's own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.

How does Ardent Health Partners, LLC compare to its competitors in key financial ratios?

The fastest way to compare Ardent Health Partners, LLC with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see Ardent Health Partners, LLC outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

What do Ardent Health Partners, LLC's liquidity and leverage ratios show?

Liquidity and leverage figures on this page are published ratios, not a verdict that Ardent Health Partners, LLC is financially strong. Current ratio is about 2.10, which is above 1.0 and can indicate more comfortable short-term liquidity. Interest coverage is about 9.74, implying a stronger ability to cover interest expenses. Debt-to-equity is about 1.68, suggesting higher leverage than a low-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.

What do Ardent Health Partners, LLC's financial ratios say about its future growth?

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If Ardent Health Partners, LLC is sustaining strong returns (for example ROE at 5.21% and ROIC at 9.26%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.